News
Recommended
- 5′-二磷酸尿嘧啶核苷-N-乙酰半乳糖胺二钠盐
- 胡椒环
- High content Red Yeast Rice
- (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamidemethanesulfonate
- velpatasvir
- Daclatasvir 2HCL
- Daclatasvir
- Asunaprevir
- Omarigliptin MK-3102
- Ledipasvir acetone
- Ribonucleic acid
- (R)-3-Amino-1-butanol
- 1,5-Bis(4-trifluoromethylphenyl)-penta-1,4-diene-3-one
- Riboflavin 5'-adenosine diphosphate disodium salt
- BETA-NICOTINAMIDE MONONUCLEOTIDE
- Ledipasvir
- cytidine 5'-diphosphocholine sodium salt dihydrate
- entecavir
- Sofosbuvir
- ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate
- Citicoline
- L-Ribose
- L-Fucose
- 2,3,4,6-Tetra-O-Pivaloyl-α-D-Glucopyranosyl Bromide
- 2-Deoxy-L-ribose
- ribavirin
- Beta-D-Ribofuranose 1,2,3,5-tetraacetate
- Thymidine
- Uridine
- 2'-O-Methylguanosine
- Guanosine hydrate
- Cytidine
- N4-Benzoylcytosine
- Adenosine – cosmetics grade
Hotline
86-21-56152668
86-21-56152668
2012 China's import and export of pharmaceutical products to new highs
Published： 2014/8/28 17:38:36
Summary Core Tip: in 2012, the product import and export value of China's pharmaceutical 80.95 billion U.S. dollars, an increase of 10.5%, a new record high. Among this, exports $ 47.6 billion, an increase of 6.9%; imports 33.35 billion U.S. dollars, up by 15.9% foreign trade surplus $ 14.25 billion, down 9.5 percent yesterday, the Health Insurance Association released last year on the import and export of China's pharmaceutical data: 2012. , product import and export value of China's pharmaceutical 80.95 billion U.S. dollars, an increase of 10.5%, a new record high. Among this, exports $ 47.6 billion, an increase of 6.9%; imports 33.35 billion U.S. dollars, up by 15.9% foreign trade surplus $ 14.25 billion, down 9.5 percent.
It is understood that three categories of export commodities, medicine, medical equipment products exports were $ 27.52 billion and $ 17.59 billion, accounting for up to 94.8% of total exports.
Among them, a noteworthy trend is: China's pharmaceutical companies are accelerating international registration certification process. According to Xu Ming, vice president of the Health Insurance Association of introduction, in 2012, China's pharmaceutical enterprises to submit to the United States Food and Drug Administration (FDA) the total number of applications reached 1,259 copies; submit CEP (bulk drug registration review) to the European Quality of Medicines (EDQM) 173 applications, representing an increase of 34.1 percent in 2011, the total number of valid certificates reached 393 copies.
In addition, the export of agents has also ushered in the development of inflection point. According to association statistics, long time, Western medicine has not been the main export products. But in 2012, Western medicine export growth, exports increase of up to 17.9%, showing a strong momentum of development.
As Huahai, in 2007 formulated the development strategy to expand overseas, to 2012 has finally entered the harvest period. Huahai 2012 results notice, the company exported preparations rapid growth over the previous year is expected to grow by about 200%. Changjiang Securities, the latest research report also expects growth in 2013 the company will continue preparations export business more than 100% higher growth will remain 2-3 years.
We can say that speed up overseas export strategy is an important starting point in Zhejiang APIs listed companies. Zhejiang Yongtai Technology shares stakeholders revealed until 2011, part of the pharmaceutical sector exports and domestic sales were flat;. To 2012 the proportion of the export business has risen to 85% the company has invested in a subsidiary in the United States, coming in the relevant product obtained after the FDA certification, is expected to carry out production and sales in the United States.
It is understood that three categories of export commodities, medicine, medical equipment products exports were $ 27.52 billion and $ 17.59 billion, accounting for up to 94.8% of total exports.
Among them, a noteworthy trend is: China's pharmaceutical companies are accelerating international registration certification process. According to Xu Ming, vice president of the Health Insurance Association of introduction, in 2012, China's pharmaceutical enterprises to submit to the United States Food and Drug Administration (FDA) the total number of applications reached 1,259 copies; submit CEP (bulk drug registration review) to the European Quality of Medicines (EDQM) 173 applications, representing an increase of 34.1 percent in 2011, the total number of valid certificates reached 393 copies.
In addition, the export of agents has also ushered in the development of inflection point. According to association statistics, long time, Western medicine has not been the main export products. But in 2012, Western medicine export growth, exports increase of up to 17.9%, showing a strong momentum of development.
As Huahai, in 2007 formulated the development strategy to expand overseas, to 2012 has finally entered the harvest period. Huahai 2012 results notice, the company exported preparations rapid growth over the previous year is expected to grow by about 200%. Changjiang Securities, the latest research report also expects growth in 2013 the company will continue preparations export business more than 100% higher growth will remain 2-3 years.
We can say that speed up overseas export strategy is an important starting point in Zhejiang APIs listed companies. Zhejiang Yongtai Technology shares stakeholders revealed until 2011, part of the pharmaceutical sector exports and domestic sales were flat;. To 2012 the proportion of the export business has risen to 85% the company has invested in a subsidiary in the United States, coming in the relevant product obtained after the FDA certification, is expected to carry out production and sales in the United States.
